These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22976931)

  • 1. B lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy.
    Youinou P; Pers JO
    Lupus; 2012 Nov; 21(13):1375-7. PubMed ID: 22976931
    [No Abstract]   [Full Text] [Related]  

  • 2. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases.
    Sun J; Lin Z; Feng J; Li Y; Shen B
    Eur J Pharmacol; 2008 Nov; 597(1-3):1-5. PubMed ID: 18793632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.
    Mackay F; Silveira PA; Brink R
    Curr Opin Immunol; 2007 Jun; 19(3):327-36. PubMed ID: 17433868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis.
    Begum-Haque S; Sharma A; Christy M; Lentini T; Ochoa-Reparaz J; Fayed IF; Mielcarz D; Haque A; Kasper LH
    J Neuroimmunol; 2010 Feb; 219(1-2):47-53. PubMed ID: 20034680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAFF, APRIL, TWE-PRIL: who's who?
    Daridon C; Youinou P; Pers JO
    Autoimmun Rev; 2008 Feb; 7(4):267-71. PubMed ID: 18295728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
    Baert L; Manfroi B; Casez O; Sturm N; Huard B
    J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases.
    Mariette X
    Joint Bone Spine; 2004 Sep; 71(5):357-60. PubMed ID: 15474382
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CD20 antibody for the treatment of systemic autoimmune diseases].
    Tanaka Y
    Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
    [No Abstract]   [Full Text] [Related]  

  • 11. CD5 positive B lymphocytes: a link between autoimmunity and B-cell oncogenesis.
    Bataille R; Klein B
    Anticancer Res; 1988; 8(4):707-10. PubMed ID: 2460021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell targeted therapy in autoimmunity.
    Blank M; Shoenfeld Y
    J Autoimmun; 2007; 28(2-3):62-8. PubMed ID: 17391915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD5: a safeguard against autoimmunity and a shield for cancer cells.
    Dalloul A
    Autoimmun Rev; 2009 Feb; 8(4):349-53. PubMed ID: 19041428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
    Zarkhin V; Li L; Sarwal MM
    Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas.
    Sutherland AP; Mackay F; Mackay CR
    Pharmacol Ther; 2006 Dec; 112(3):774-86. PubMed ID: 16863659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The late news on baff in autoimmune diseases.
    Youinou P; Pers JO
    Autoimmun Rev; 2010 Oct; 9(12):804-6. PubMed ID: 20656068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell-ablative therapy for the treatment of autoimmune diseases.
    Patel DD
    Arthritis Rheum; 2002 Aug; 46(8):1984-5. PubMed ID: 12209499
    [No Abstract]   [Full Text] [Related]  

  • 18. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.
    Whelan BR; Isenberg DA
    Rheumatology (Oxford); 2009 May; 48(5):594-5. PubMed ID: 19254917
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospects for B-cell-targeted therapy in autoimmune disease.
    Edwards JC; Cambridge G
    Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
    [No Abstract]   [Full Text] [Related]  

  • 20. The BAFF/APRIL system: an important player in systemic rheumatic diseases.
    Mackay F; Sierro F; Grey ST; Gordon TP
    Curr Dir Autoimmun; 2005; 8():243-65. PubMed ID: 15564724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.